ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

opevesostat

Also written as “Opevesostat”, “MK-5684” and “ODM-208”.

Its studies are mostly in Prostatic Neoplasms · Prostatic Neoplasms, Castration-Resistant · Neoplasms · Kidney Failure, Chronic, led by 2 companies.

Drug pageOpevesostat: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 13, 202313 company-led studies, 5 open or runningLicense: Orion → Merck, Jul 2024Next primary completion: Nov 4, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck124 open or runningphase 3since Nov 13, 2023Oct 23, 2023Nov 4, 2027phase 2 · NCT06979596
Orion Corporation, Orion Pharmaits history only11 open or runningphase 2since Feb 12, 2018Feb 12, 2018none ahead
  • Named in Merck’s own pipeline as opevesostat (MK-5684), phase 3, as of Nov 2, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

  • LicenseMerck licensed it from Orion, for worldwide rights, in place of their co-development.Announced Jul 1, 2024 · Source: Merck, Jul 1, 2024

History and studies of Merck only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Aug 6, 2023Named opevesostatINNProposed as its International Nonproprietary Name in WHO's List 129 · before, MK-5684, ODM-208
  2. Oct 23, 2023First study: phase 1 study in Prostatic NeoplasmsFirst studyNCT06104449 · 7 enrolled · Japan
  3. Nov 13, 20232 phase 3 studiesNCT06136650, NCT06136624
  4. Nov 13, 2023Phase 1 study in Prostatic NeoplasmsNCT06136598 · 14 enrolled · China
  5. Apr 3, 2024Phase 2 study in Prostatic Neoplasms, Castration-ResistantNCT06353386 · 220 enrolled · United States, Australia, Canada and more
  6. Jul 1, 2024Merck licensed it from OrionLicenseWorldwide rights, in place of their co-development · announced · Merck
  7. Aug 12, 20242 phase 1 studies in Prostatic NeoplasmsNCT06554639, NCT06566989
  8. Oct 7, 2024Phase 1 study in HealthyNCT06633419 · 14 enrolled · United States
  9. Feb 3, 20252 phase 1 studiesNCT06814132, NCT06860243
  10. May 13, 2025Phase 2 study in NeoplasmsNCT06979596 · 250 planned · United States, Argentina, Brazil and more
  11. Apr 17, 2026Phase 1 study in HealthyNCT07548606 · 14 enrolled · United States
  12. Nov 5, 2026Primary completion moved from 2028-08-02 to 2028-11-30Date moved laterphase 3 · +4 months · NCT06136624

Ahead

  1. Nov 4, 2027Primary completion: phase 2 study in NeoplasmsNCT06979596
  2. May 10, 2028Primary completion: phase 3 study in Prostatic NeoplasmsNCT06136650
  3. Nov 30, 2028Primary completion: phase 3 study in Prostate Cancer MetastaticNCT06136624
  4. Jan 15, 2029Primary completion: phase 2 study in Prostatic Neoplasms, Castration-ResistantNCT06353386

TargetBeta

“An orally bioavailable, non-steroidal, selective inhibitor of the enzyme cytochrome 450 side-chain cleavage (scc) (CYP11A1), with potential antineoplastic activity. Upon oral administration, opevesostat targets, binds to and inhibits the activity of CYP11A1. This prevents the synthesis of all ste…”NCIt, read by Claude
“An orally bioavailable, non-steroidal, selective inhibitor of the enzyme cytochrome 450 side-chain cleavage (scc) (CYP11A1), ”NCIt, by rule

Other programs on CYP11A1

ProgramCompanyFurthest phaseStudies
CYP11A1 Inhibitor ACE-232ruleacerand-therapeutics-hong-kong-limitedphase 11

Studies

All 12 Merck leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07548606Healthy · United States1CompletedJun 1, 202614
NCT06979596Neoplasms · United States, Argentina, Brazil and more2RecruitingNov 4, 2027250
NCT06860243Hepatic Impairment · United States1CompletedFeb 9, 202616
NCT06814132Kidney Failure, Chronic · United States1CompletedOct 4, 202524
NCT06633419Healthy · United States1CompletedFeb 12, 202514
NCT06566989Prostatic Neoplasms · United Kingdom1CompletedOct 17, 20248
NCT06554639Prostatic Neoplasms · United States1CompletedAug 5, 202412
NCT06353386Prostatic Neoplasms, Castration-Resistant · United States, Australia, Canada and more2Active, not recruitingJan 15, 2029220
NCT06136650Prostatic Neoplasms · United States, Australia, Brazil and more3RecruitingMay 10, 20281,314
NCT06136624Prostate Cancer Metastatic · United States, Argentina, Australia and more3RecruitingNov 30, 20281,310
NCT06136598Prostatic Neoplasms · China1CompletedMar 9, 202614
NCT06104449Prostatic Neoplasms · Japan1CompletedFeb 20, 20267

How it is read

Names in the registry

  • “Opevesostat”, 9 entries
  • “MK-5684”, 2 entries
  • “ODM-208”, 1 entry
  • “[¹⁴C]Opevesostat”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.